Genmab — November 2012
-
tjek lige om Carnegie er igang igen
-
nej ser ikke sådan ud
-
den er steget 200% på et år....gevinsthjemtagning
-
aktier der er steget 200% opfører sig tit sådan at de skal have en pause, hvor det fundamentale lige skal synke ind i aktiens dna. Så skal markedet overveje...er den steget for meget? eller er den fortsat billig....? Det hele er meget logisk
-
nej en yoyo går ikke 200% op
-
Der er altså mange guldkorn på ASH:The combination of lenalidomide and ofatumumab was well tolerated by most patients. The patients with indolent NHL had a high response rate of 83% and a 1-year PFS of 67% https://ash.confex.com/ash/2012/webprogram/Paper50366.html
-
det ser godt ud gentogen. Hvad var sammenligningsdata på ritux?
-
ORR på 40% på refrac og relaps
-
er pænt flot
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind